Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Alembic Pharmaceuticals Ltd (APL) is a pharmaceutical company that manufactures and markets pharmaceutical products. Its activities include the production of Indian formulations, international generics, and active pharmaceutical ingredients (APIs). The company's products include oral solids, oncology on-screen display, general and oncology injectables, generic formulations, and ophthalmic and dermatology products. Alembic Pharmaceuticals offers products for various therapeutic areas, including cardiovascular, analgesics, gynecology, cough and cold, gastroenterology, ophthalmology, anti-diabetics, orthopedics, urology, and dermatological therapies. The company operates in India, the US, Canada, Switzerland, Ukraine, Algeria, Australia, Malta, China, Brazil, and South Africa. APL is headquartered in Vadodara, Gujarat, India.
Headquarters
India
Address
Alembic Road, Vadodara, Gujarat, 390003
Website
alembicpharmaceuticals.com
Telephone
91 265 6637000
No of Employees
16,571
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
APLLTD (NSE)
Revenue (2025)
$843.0M
10.1%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
15.7%
(2025 vs 2024)
Market Cap*
$1.7B
Net Profit Margin (2025)
XYZ
5.2%
(2025 vs 2024)
* As of and is in US$
Alembic Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Formulations |
| Generics |
| Active Pharmaceutical Ingredients |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In June, the company secured tentative approval from the US Food & Drug Administration for its Abbreviated New Drug Application (ANDA) Larotrectinib Capsules, 25 mg and 100 mg. |
| 2026 | Regulatory Approval | In June, the company secured final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application Oseltamivir Phosphate for Oral Suspension, 6 mg/mL. |
| 2026 | Contracts/Agreements | In June, the company entered into an agreement to acquire a 45% stake in 17989377 Canada, Inc. |
Competitor Comparison
| Key Parameters | Alembic Pharmaceuticals Ltd | Aurobindo Pharma Ltd | Laurus Labs Ltd | Gland Pharma Ltd | Aarti Drugs Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Vadodara | Hyderabad | Hyderabad | Hyderabad | Mumbai |
| State/Province | Gujarat | Telangana | Telangana | Telangana | Maharashtra |
| No. of Employees | 16,571 | 9,107 | 7,059 | 4,351 | 2,067 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Chirayu Ramanbhai Amin | Chairman | Executive Board | 2026 | - |
| Pranav Chirayu Amin | Managing Director; Director | Executive Board | 2016 | 49 |
| Shaunak Chirayu Amin | Director; Managing Director | Executive Board | - | 47 |
| Pradeep Chakravarthy | Head - Global Quality | Senior Management | - | - |
| Ramesh Kumar | Head - Research and Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer